Prostaglandin E1 in infants with congenital diaphragmatic hernia (CDH) and life-threatening pulmonary hypertension.
Congenital diaphragmatic hernia
Ductus arteriosus
Prostaglandin E1
Pulmonary hypertension
Journal
Journal of pediatric surgery
ISSN: 1531-5037
Titre abrégé: J Pediatr Surg
Pays: United States
ID NLM: 0052631
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
08
07
2019
revised:
18
12
2019
accepted:
09
01
2020
pubmed:
18
2
2020
medline:
2
1
2021
entrez:
17
2
2020
Statut:
ppublish
Résumé
Suprasystemic pulmonary hypertension (PH) is highly predictive of pulmonary morbidity and death in infants with congenital diaphragmatic hernia (CDH). To report the effects and tolerability of Prostaglandin E Newborn infants with isolated CDH and life-threatening PH defined by an acute worsening of the cardiorespiratory function, and bidirectional or exclusive right-to-left shunting across the ductus arteriosus (DA) with an acceleration of the blood flow >1.5 m.s 18 infants (out of 102 in the cohort) were included in the study (gestational age: 39 ± 2 weeks). The median FiO PGE Treatment study. Level III.
Sections du résumé
BACKGROUND
BACKGROUND
Suprasystemic pulmonary hypertension (PH) is highly predictive of pulmonary morbidity and death in infants with congenital diaphragmatic hernia (CDH).
OBJECTIVES
OBJECTIVE
To report the effects and tolerability of Prostaglandin E
METHODS
METHODS
Newborn infants with isolated CDH and life-threatening PH defined by an acute worsening of the cardiorespiratory function, and bidirectional or exclusive right-to-left shunting across the ductus arteriosus (DA) with an acceleration of the blood flow >1.5 m.s
RESULTS
RESULTS
18 infants (out of 102 in the cohort) were included in the study (gestational age: 39 ± 2 weeks). The median FiO
CONCLUSIONS
CONCLUSIONS
PGE
TYPE OF STUDY
METHODS
Treatment study.
LEVEL OF EVIDENCE
METHODS
Level III.
Identifiants
pubmed: 32061366
pii: S0022-3468(20)30033-6
doi: 10.1016/j.jpedsurg.2020.01.008
pii:
doi:
Substances chimiques
Vasodilator Agents
0
Alprostadil
F5TD010360
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1872-1878Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.